New Drugs
| Brand/Generic | Company | Description |
|---|---|---|
|
Addyi flibanserin |
Sprout (U.S.)/Therapeutic Pro | A serotonin agonist/antagonist for premenopausal women with hypoactive sexual desire disorder. |
|
Afluria Tetra influenza vaccine |
Seqirus | Quadrivalent influenza vaccine for preventing influenza. |
|
Aimovig erenumab |
Novartis | A calcitonin gene-related peptide receptor antagonist for migraine prevention. |
|
Alphanate antihemophilic/von Willebrand factor |
Grifols Canada | For prevention and treatment of bleeding in von Willebrand disease. |
|
Alunbrig brigatinib |
Takeda | A kinase inhibitor for a certain type of non-small cell lung cancer. |
|
Belsomra suvorexant |
Merck | An orexin receptor antagonist for insomnia. |
|
Besponsa inotuzumab ozogamicin |
Pfizer | A CD22-directed antibody-drug conjugate for advanced B-cell precursor acute lymphoblastic leukemia. |
|
Bevespi Aerosphere glycopyrronium/formoterol |
AstraZeneca | New LAMA/LABA combination inhaler for COPD. |
|
Biktarvy bictegravir/emtricitabine/tenofovir alafenamide |
Gilead Sciences | A combination drug for HIV-1 infection. |
|
BioThrax anthrax vaccine adsorbed |
Emergent BioSolutions | A vaccine for high-risk individuals to prevent anthrax. |
|
Brineura cerliponase alfa |
BioMarin | An enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 disease. |
|
Cabometyx cabozantinib |
Ipsen Biopharm. | An oral tyrosine kinase inhibitor for advanced renal cell carcinoma. |
|
Contrave naltrexone/bupropion |
Valeant | A combination opioid antagonist and antidepressant for weight management. |
|
Cresemba isavuconazole |
Avir | An IV/oral azole antifungal for invasive aspergillosis or mucormycosis. |
|
Crysvita burosumab |
Kyowa Kirin (U.K.)/Innomar | A fibroblast growth factor 23 inhibitor for X-linked hypophosphatemia. |
|
Cutaquig immunoglobulin G |
Octapharma | Human immunoglobulin given by SC infusion for primary or secondary immune deficiency. |
|
Erleada apalutamide |
Janssen | An androgen receptor inhibitor for non-metastatic, castration-resistant prostate cancer. |
|
Eucrisa crisaborole |
Pfizer | A topical PDE-4 inhibitor for mild/moderate atopic dermatitis. |
|
Fasenra benralizumab |
Astra Zeneca | A monoclonal antibody for add-on maintenance treatment of severe eosinophilic asthma. |
|
Folotyn pralatrexate |
Servier | An IV folate inhibitor for treatment of relapsed/refractory peripheral T-cell lymphoma. |
|
Fulphila pegfilgrastim |
BGP Pharma/Mylan | A biosimilar to Neulasta. |
|
Hadlima adalimumab |
Samsung Bioepis/ Merck | First biosimilar to Humira. |
|
Hemlibra emicizumab |
Hoffmann-La Roche | Treatment to reduce the frequency of bleeding episodes in hemophilia A. |
|
Jivi antihemophilic factor |
Bayer | A PEGylated antihemophilic factor for treatment/prevention of bleeding in hemophilia A. |
|
Kisqali ribociclib |
Novartis | A kinase inhibitor for postmenopausal women with advanced breast cancer. |
|
Kymriah tisagenlecleucel |
Novartis | T-cell immunotherapy for B-cell acute lymphoblastic leukemia or B-cell lymphoma. |
|
Lapelga pegfilgrastim |
Apotex | First biosimilar to Neulasta. |
|
Lonsurf trifluridine/tipiracil |
Taiho Pharma | New oral combination formulation for metastatic colorectal cancer. |
|
Mar-Cidofovir cidofovir |
Marcan | An IV antiviral for CMV retinitis in adults with AIDS. |
|
Mezera mesalazine |
Avir Pharma | A rectal foam enema for ulcerative colitis and rectal suppository for ulcerative proctitis. |
|
Mvasi bevacizumab |
Amgen | A biosimilar to Avastin, for colorectal & non-small cell lung cancer. |
|
Nuceiva prabotulinumtoxinA |
Evolus (U.S.) | A neuromuscular blocking agent for temporarily improving forehead frown lines. |
|
Olumiant baricitinib |
Lilly | An oral Janus kinase inhibitor for rheumatoid arthritis. |
|
Orilissa elagolix |
AbbVie | A gonadotropin-releasing hormone receptor antagonist for pain associated with endometriosis. |
|
Ozempic semaglutide |
Novo Nordisk | A GLP-1 agonist for type 2 diabetes. |
|
Panhematin hemin |
Recordati Rare Diseases | An IV porphyrin synthesis inhibitor for recurrent attacks of acute intermittent porphyria related to the menstrual cycle. |
|
Penthrox methoxyflurane |
Purdue Pharma | A self-administered inhaled anesthetic/analgesic for short-term relief of moderate to severe acute pain. |
|
Pifeltro doravirine |
Merck | An NNRTI antiretroviral agent for HIV-1 infection. |
|
Radicava edaravone |
Mitsubishi Tanabe | An intravenous treatment for amyotrophic lateral sclerosis (ALS). |
|
Rekovelle follitropin delta |
Ferring | A recombinant human FSH for ovarian stimulation. |
|
Siliq brodalumab |
Valeant | An IL-17RA blocker for moderate to severe plaque psoriasis. |
|
Steglatro ertugliflozin |
Merck | An SGLT2 inhibitor for type 2 diabetes. |
|
Symdeko ivacaftor/tezacaftor |
Vertex | A combination formulation for cystic fibrosis. |
|
Symtuza darunavir/cobicistat/emtricitabine/ tenofovir alafenamide |
Janssen | New combination regimen for HIV-1 infection. |
|
Takhzyro lanadelumab |
Shire | A plasma kallikrein inhibitor for routine prevention of hereditary angioedema attacks. |
|
Tegsedi inotersen |
Akcea (US)/Innomar | An antisense oligonucleotide for polyneuropathy of hereditary transthyretin-mediated amyloidosis. |
|
Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol |
GSK | A new combination oral inhaler for COPD. |
|
Unituxin dinutuximab |
United Therapeutics (U.S.) | A monoclonal antibody for children with neuroblastoma. |
|
Velphoro sucroferric oxyhydroxide |
Vifor Fresenius/Innomar Strate | A chewable, calcium-free phosphate binder. |
|
Veltassa patiromer |
Vifor Fresenius | An oral potassium binder for hyperkalemia. |
|
Vyzulta latanoprostene bunod |
Bausch Health | A prostaglandin analogue ophthalmic solution to lower intraocular pressure. |
|
Xermelo telotristat |
Ipsen Biopharm | An oral tryptophan hydroxylase inhibitor for refractory carcinoid syndrome diarrhea. |
|
Xydalba dalbavancin |
Cipher | A single-dose IV lipoglycopeptide antibiotic for acute bacterial skin/skin structure infections. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Arbesda fluticasone/salmeterol |
Teva | A steroid/LABA combination oral inhaler for asthma. |
|
Bevespi Aerosphere glycopyrronium/formoterol |
AstraZeneca | New LAMA/LABA combination inhaler for COPD. |
|
Bydureon BCise exenatide |
AstraZeneca | New formulation of exenatide in a pen device. |
|
Contrave naltrexone/bupropion |
Valeant | A combination opioid antagonist and antidepressant for weight management. |
|
Delstrigo doravirine/lamivudine/tenofovir DF |
Merck | A combination antiretroviral for HIV-1 infection. |
|
Fucibet betamethasone/fusidic acid |
Leo Pharma | An antibiotic/steroid topical cream for eczema. |
|
Iluvien fluocinolone acetonide |
Knight Therapeutics | A corticosteroid intravitreal implant for diabetic macular edema. |
|
Juluca rilpivirine/ dolutegravir |
ViiV Healthcare | New combination formulation for HIV-1 infection. |
|
Mezera mesalazine |
Avir Pharma | A rectal foam enema for ulcerative colitis and rectal suppository for ulcerative proctitis. |
|
Monoferric iron isomaltoside 1000 |
Pharmacosmos/Pfizer | IV iron for iron deficiency anemia in adults. |
|
Ofirmev acetaminophen |
Avir Pharma | New injectable formulation for pain and fever. |
|
Probuphine buprenorphine |
Knight Therapeutics | A partial opioid agonist subdermal implant for management of opioid dependence. |
|
Rayaldee calcifediol |
Vifor Fresenius/Innomar Strat | A vitamin D3 analogue for secondary hyperparathyroidism in patients with chronic kidney disease. |
|
Segluromet ertugliflozin/ metformin |
Merck | An SGLT2 inhibitor/biguanide combo for use in type 2 diabetes. |
|
Soliqua insulin glargine/lixisenatide |
Sanofi-Aventis | An insulin/GLP-1 agonist combination for type 2 diabetes. |
|
Steglujan ertugliflozin/ sitagliptin |
Merck | An SGLT2 inhibitor/DPP-4 inhibitor combination for type 2 diabetes. |
|
Stromectol ivermectin |
Merck | An oral antiparasitic for intestinal strongyloidiasis and onchocerciasis. |
|
Sublocade buprenorphine |
Indivior (UK) | New extended-release injection formulation for opioid use disorder. |
|
Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide Janssen |
Janssen | New combination regimen for HIV-1 infection. |
|
Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol |
GSK | A new combination oral inhaler for COPD. |
|
Verkazia cyclosporine |
Santen (U.S.)/ McKesson Specia | A 0.1% ophthalmic emulsion for severe vernal keratoconjunctivitis in children/adolescents. |
|
Xultophy insulin degludec/liraglutide |
Novo Nordisk | A combination long-acting insulin and GLP-1 agonist for type 2 diabetes. |
|
Zinbryta daclizumab |
Biogen | Voluntary withdrawal due to safety concerns, including reports of severe liver damage and immune-related conditions. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Zinbryta daclizumab |
Biogen | Voluntary withdrawal due to safety concerns, including reports of severe liver damage and immune-related conditions. |